Involvement of Expression of MiR33-5p and ABCA1 in Human Peripheral Blood Mononuclear Cells in Coronary Artery Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Aug 29

PMID 39201292

Authors

Yazmin Estela Torres-Paz

Ricardo Gamboa

Giovanny Fuentevilla-Alvarez

Guillermo Cardoso-Saldana

Rocio Martinez-Alvarado

Maria Elena Soto

Claudia Huesca-Gomez

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRs) are small non-coding RNAs that regulate gene expression post-transcriptionally and are crucial in lipid metabolism. ATP-binding cassette transporter A1 (ABCA1) is essential for cholesterol efflux from cells to high-density lipoprotein (HDL). Dysregulation of miRs targeting can affect cholesterol homeostasis and contribute to coronary artery disease (CAD). This study aimed to investigate the expression of miRs targeting in human monocytes, their role in cholesterol efflux, and their relationship with CAD. We included 50 control and 50 CAD patients. RT-qPCR examined the expression of miR-33a-5p, miR-26a-5p, and miR-144-3p in monocytes. Logistic regression analysis explored the association between these miRs and CAD. HDL's cholesterol acceptance was analyzed using the J774A.1 cell line. Results showed that miR-26a-5p ( = 0.027) and ( = 0.003) expression levels were higher in CAD patients, while miR-33a-5p ( < 0.001) levels were lower. Downregulation of miR-33a-5p and upregulation of were linked to a lower CAD risk. Atorvastatin upregulated mRNA, and metformin downregulated miR-26a-5p in CAD patients. Decreased cholesterol efflux correlated with higher CAD risk and inversely with miRs in controls. Reduced miR-33a-5p expression and increased expression are associated with decreased CAD risk. miR deregulation in monocytes may influence atherosclerotic plaque formation by regulating cholesterol efflux. Atorvastatin and metformin could offer protective effects by modulating miR-33a-5p, miR-26a-5p, and , suggesting potential therapeutic strategies for CAD prognosis and treatment.

References

Khera A, Demler O, Adelman S, Collins H, Glynn R, Ridker P . Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation. 2017; 135(25):2494-2504. PMC: 5490983. DOI: 10.1161/CIRCULATIONAHA.116.025678. View

Cerda A, Hirata M, Hirata R . Molecular mechanisms underlying statin effects on genes involved in the reverse cholesterol transport. Drug Metabol Drug Interact. 2012; 27(2):101-11. DOI: 10.1515/dmdi-2012-0007. View

Torres-Paz Y, Gamboa R, Fuentevilla-Alvarez G, Soto M, Gonzalez-Moyotl N, Martinez-Alvarado R . Overexpression of microRNA-21-5p and microRNA-221-5p in Monocytes Increases the Risk of Developing Coronary Artery Disease. Int J Mol Sci. 2023; 24(10). PMC: 10218481. DOI: 10.3390/ijms24108641. View

Sparrow C, Baffic J, Lam M, Lund E, Adams A, Fu X . A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem. 2002; 277(12):10021-7. DOI: 10.1074/jbc.M108225200. View

Delong D, DeLong E, Wood P, Lippel K, Rifkind B . A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study. JAMA. 1986; 256(17):2372-7. View

Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A . Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 2015; 3(7):507-13. PMC: 4648056. DOI: 10.1016/S2213-8587(15)00126-6. View

Mirzaei H, Ferns G, Avan A, Mobarhan M . Cytokines and MicroRNA in Coronary Artery Disease. Adv Clin Chem. 2017; 82:47-70. DOI: 10.1016/bs.acc.2017.06.004. View

Wang X, Collins H, Ranalletta M, Fuki I, Billheimer J, Rothblat G . Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007; 117(8):2216-24. PMC: 1924499. DOI: 10.1172/JCI32057. View

Li X, Tang W, Mosior M, Huang Y, Wu Y, Matter W . Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol. 2013; 33(7):1696-705. PMC: 3743250. DOI: 10.1161/ATVBAHA.113.301373. View

10.

Argmann C, Edwards J, Sawyez C, ONeil C, Hegele R, Pickering J . Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem. 2005; 280(23):22212-21. DOI: 10.1074/jbc.M502761200. View

11.

Miyakawa Y, Kagaya K, Watanabe K, Fukazawa Y . Characteristics of macrophage activation by gamma interferon for tumor cytotoxicity in peritoneal macrophages and macrophage cell line J774.1. Microbiol Immunol. 1989; 33(12):1027-38. DOI: 10.1111/j.1348-0421.1989.tb03160.x. View

12.

Peters L, Biessen E, Hohl M, Weber C, van der Vorst E, Santovito D . Small Things Matter: Relevance of MicroRNAs in Cardiovascular Disease. Front Physiol. 2020; 11:793. PMC: 7358539. DOI: 10.3389/fphys.2020.00793. View

13.

Du X, Kim M, Hou L, Le Goff W, Chapman M, Van Eck M . HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ Res. 2015; 116(7):1133-42. DOI: 10.1161/CIRCRESAHA.116.305485. View

14.

Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K . MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci U S A. 2010; 107(40):17321-6. PMC: 2951399. DOI: 10.1073/pnas.1008499107. View

15.

de Aguiar Vallim T, Tarling E, Kim T, Civelek M, Baldan A, Esau C . MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor. Circ Res. 2013; 112(12):1602-12. PMC: 3995747. DOI: 10.1161/CIRCRESAHA.112.300648. View

16.

DeWood M, Spores J, Notske R, Mouser L, Burroughs R, Golden M . Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980; 303(16):897-902. DOI: 10.1056/NEJM198010163031601. View

17.

Sun D, Zhang J, Xie J, Wei W, Chen M, Zhao X . MiR-26 controls LXR-dependent cholesterol efflux by targeting ABCA1 and ARL7. FEBS Lett. 2012; 586(10):1472-9. DOI: 10.1016/j.febslet.2012.03.068. View

18.

Zambrano T, Hirata R, Hirata M, Cerda A, Salazar L . Statins differentially modulate microRNAs expression in peripheral cells of hyperlipidemic subjects: A pilot study. Eur J Pharm Sci. 2018; 117:55-61. DOI: 10.1016/j.ejps.2018.02.007. View

19.

Li J, Chen H, Ren J, Song J, Zhang F, Zhang J . Effects of statin on circulating microRNAome and predicted function regulatory network in patients with unstable angina. BMC Med Genomics. 2015; 8:12. PMC: 4364658. DOI: 10.1186/s12920-015-0082-4. View

20.

Rye K, Barter P . Cardioprotective functions of HDLs. J Lipid Res. 2013; 55(2):168-79. PMC: 3886656. DOI: 10.1194/jlr.R039297. View